BioPlus Acquisition Corp. Class A Ordinary Shares
BIOS
BIOS was delisted on the 6th of October, 2023.
32 hedge funds and large institutions have $132M invested in BioPlus Acquisition Corp. Class A Ordinary Shares in 2023 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 9 increasing their positions, 12 reducing their positions, and 34 closing their positions.
25% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 12
43% less capital invested
Capital invested by funds: $231M → $132M (-$98.6M)
48% less funds holding
Funds holding: 61 → 32 (-29)
82% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 34
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MSU
Mizuho Securities USA
New York
|
+$10.7M |
| 2 |
QL
Quarry LP
New York
|
+$4.79M |
| 3 |
FTCM
First Trust Capital Management
Chicago,
Illinois
|
+$4.27M |
| 4 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
+$3.78M |
| 5 |
CC
Centiva Capital
New York
|
+$3.47M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CF
Cantor Fitzgerald
New York
|
-$13.2M |
| 2 |
PMAM
Picton Mahoney Asset Management
Toronto,
Ontario, Canada
|
-$12M |
| 3 |
AC
Aristeia Capital
Greenwich,
Connecticut
|
-$11.3M |
| 4 |
Calamos Advisors
Naperville,
Illinois
|
-$10.4M |
| 5 |
D.E. Shaw & Co
New York
|
-$9.33M |
BIOS Hedge Fund Activity: Q2 2023 in Review
32 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in BioPlus Acquisition Corp. Class A Ordinary Shares (BIOS) for Q2 2023, worth a combined $132M — down 43% from $231M a quarter earlier.
Sellers outnumbered buyers: 34 funds closed out of BIOS and 6 opened new positions — a net loss of 28 holders — while 12 trimmed existing stakes and 9 added.
The largest buyer was Mizuho Securities USA, opening a new position worth an estimated $10.7M. The largest seller was Cantor Fitzgerald, exiting entirely with an estimated $13.2M sold.
- 32 institutional investors held BioPlus Acquisition Corp. Class A Ordinary Shares (BIOS) as of Q2 2023, down from 61 in Q1 2023.
- Funds reported $132M of BioPlus Acquisition Corp. Class A Ordinary Shares stock for Q2 2023, down 43% quarter-over-quarter.
- 6 funds opened new BioPlus Acquisition Corp. Class A Ordinary Shares positions in Q2 2023 and 34 closed out, a net change of -28 holders.
- The largest BioPlus Acquisition Corp. Class A Ordinary Shares buyer in Q2 2023 was Mizuho Securities USA, an estimated $10.7M added.
- The largest BioPlus Acquisition Corp. Class A Ordinary Shares seller in Q2 2023 was Cantor Fitzgerald, an estimated $13.2M sold.
Based on aggregated 13F filings for Q2 2023.